Your Article Summary
See Latest ArticlesCosts of second-generation antihistamines in the treatment of allergic rhinitis: US perspective
Current Medical Research and Opinion, 06/26/09
Hay JW et al. - Preliminary evidence suggests that newer SGAs offer clinical, pharmacodynamic, and pharmacokinetic advantages that may translate into superior cost-effectiveness in the treatment of AR. Further study is warranted to clarify the pharmacoeconomic impact of the newer SGAs and to establish their relative cost-effectiveness.
Joel W. Hay, 07/13/09
| The direct costs associated with allergic rhinitis (AR) exceeded $11 billion in 2005, with nearly 60% of the total expenditure spent on prescription medications. The majority of individuals with AR in the U.S. are treated with antihistamines; approximately two thirds of those use first-generation antihistamines (FGAs) and one third uses second-generation antihistamines (SGAs). Although less expensive per unit use, FGAs may actually result in increased overall medical expenditures compared with SGAs owing to lost productivity and increased emergency department visits related to adverse events. Our recent literature review demonstrates that SGAs offer clinical, pharmacodynamic, and pharmacokinetic advantages that may translate into greater cost-effectiveness in the treatment of AR. Further study is warranted to clarify the pharmacoeconomic impact of SGAs and to establish their relative cost-effectiveness over FGAs. Current managed care policies that restrict the use of prescription vs. over-the-counter SGAs should be reexamined for cost-effectiveness. |
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders
Journal of Dermatological Treatment , 12/04/09
Non-psoriatic dermatologic uses of monoclonal antibody therapy
Journal of Dermatological Treatment , 12/04/09
Does Simvastatin Cause More Myotoxicity Compared with Other Statins
Annals of Pharmacotherapy, 12/03/09
Today in Pharmacoeconomics...keeping you current
Receive free subspecialty "5-minute updates" via email
Early and Late Direct Costs in a Southern African Antiretroviral Treatment Programme: A Retrospective Cohort Analysis
PLoS Medicine, 12/04/09
Economic Evaluation of Pharmacotherapy of Migraine Pain: A Review of the Literature
Journal Of Pain & Palliative Care Pharmacotherapy, 12/02/09
Imipenem Resistance in Pseudomonas aeruginosa: Emergence, Epidemiology, and Impact on Clinical and Economic Outcomes
Infection Control and Hospital Epidemiology, 12/02/09
Today in Pharmacokinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study
Annals of Oncology, 12/04/09
Does co-administration of paroxetine change oxycodone analgesia: An interaction study in chronic pain patients
Scandinavian Journal of Pain, 12/04/09
Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib
Clinical Pharmacology & Therapeutics, 12/03/09